LLY

Eli Lilly and Company (LLY) | Rumor.io

Eli Lilly

LLY

Attention (50-day avg)0.09%

Attention rank (50-day avg)#101

Bullish sentiment (50-day avg)94%

Price to earnings ratio39.7

Market capitalization1.1T

Earnings per share29.8

Dividend yield (TTM)0.58%

Revenue (annual)65.2B

Net income (annual)20.6B

Social

What share of all stock conversation is about LLY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.16% +0.07	0.31% +0.23	0.1% -0.01	0.21% +0.08

Sep 29

Eli Lilly's once-weekly basal insulin, Onswik, has won US FDA approval, and Olumiant's label has been expanded to include adolescents with severe alopecia.
The company's incretin trends are strong, with a 48% increase in revenue and 60% increase in volume in Q2, and guidance implies H2 revenue of $21.1-22.1B a quarter.
Lilly's CEO has reported that a third of new GLP-1 pill patients are on Wegovy, and 700k seniors have started treatment after Medicare coverage, contributing to the stock's 51% increase in a year.

Generated by AI

Sentiment

Of the messages about LLY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	80% -18.56	96.91% +8.38	95.27% +7.94	90.14% +17.81
Bearish	20% +18.56	3.09% -8.38	4.73% -7.94	9.86% -17.81

Bullish· Sep 22

$LLY has a strong position in the oral GLP-1 market, with the company capturing 70% of new senior patients and its oral GLP-1 pill winning one-third of new GLP-1 pill starts.
$LLY is expected to see significant growth in the oral obesity opportunity, with the company's CEO stating that one-third of new GLP-1 pill patients are now choosing Foundayo.
$LLY's manufacturing capacity is being ramped up, with a new $6.5B Houston manufacturing facility being built to produce Foundayo's active ingredient, supporting the company's long-term supply plans.

Bearish· Aug 5

$LLY's EPS forecasts have been revised lower in recent weeks, creating space for a potential beat, but 80% of the Yes on the $6.79 bar looks high on this setup.
$LLY's performance is underperforming Novo Nordisk, with its stock price still in the 2021 range and down 12% over the last 5 years.
$LLY's GD1 program has been dropped, removing a potential player from the Gaucher disease race, and pipeline execution remains a concern for investors.

Generated by AI

Topics

Of the messages about LLY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Macro	0%	46.7%	39.87%	55.65%
Technical Analysis	0%	0.22%	0.92%	4.96%
Announcements	98.37%	3.33%	11.68%	8.89%
Controversies	0.81%	3.02%	5.01%	1.41%
Analysts	0%	46.73%	41.16%	23.45%
Earnings	0.81%	0.01%	1.36%	5.64%

Earnings· Aug 5

$LLY's Q2 earnings beat expectations, with revenue of $22.97B vs. $20.7B estimated, and adjusted EPS of $8.38 vs. $6.01 estimated.
The company raised its FY26 revenue guidance to $85B-$87B from $82B-$85B, driven by strong demand for its obesity drugs Mounjaro and Zepbound.
Mounjaro revenue was $9.9B, up 91% YoY, and Zepbound revenue was $4.9B, beating estimates of $4.6B.

Analysts· May 27

BofA Securities reiterates a Buy rating on LLY with a price target of $1251, citing the company's dominant market position in the GLP-1 category and underappreciated growth outlook.
The analyst believes LLY's growth prospects are being underappreciated by the market, with a promising obesity pipeline that could drive future growth.
The company's short-term price action after earnings can be brutal, but it doesn't always change the longer-term trend, according to the analyst.

Announcements· Sep 22

Eli Lilly broke ground on a $6.5B Houston facility to produce active ingredients for Foundayo and other medicines, with operations expected by 2030, creating 600+ permanent jobs and 4,000 temporary ones.
The company's fortunes have reversed since the 2021 arrival of Wegovy propelled its valuation above $600 billion, with shares tumbling more than 70% from their record highs due to stiff competition from US rival Eli Lilly.
Eli Lilly received full FDA approval for Inluriyo in ESR1-Mutated Breast Cancer, with a price target of $1,250 set by TD Cowen.

Controversies· Aug 12

Eli Lilly has filed six lawsuits against U.S. entities accused of selling retatrutide products, including compounding pharmacies and medical spas, and has referred over 200 individuals and entities to regulators.
The lawsuits signal Lilly's aggressive move to protect its pipeline ahead of potential approval, and could impact the grey market for retatrutide.
The company is pushing card processors to cut off the black-market sellers, and has urged platforms to block them, as it continues to crack down on the illegal sale of its experimental obesity drug.

Macro· May 12

Eli Lilly's partnership with Takeda has potential milestones of up to $2.1 billion and tiered double-digit royalties.
Eli Lilly's partnership with the company has potential milestones of up to $1.7 billion and tiered double-digit royalties.
Analysts have set an average price target for Eli Lilly of $9.

Technical Analysis· Aug 20

The stock broke through historical highs and demonstrated significant buying interest, with a 50% increase in volume compared to the average.
A potential head and shoulders pattern is forming, which could indicate a strong upward momentum and a possible target price of $1350.
The stock has a strong bullish momentum, with a confirmed breakout and a potential target of $1506.7 or higher, while dips proposed ended in the #bluebox area.

Generated by AI

Community

Of the messages about LLY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	8.98%	85.92%	69.57%	33.32%
Newcomers	91.02%	14.08%	30.43%	66.68%

Regulars· Sep 29

Eli Lilly's Retatrutide showed a 20.8% average weight loss over 80 weeks in phase 3 trials, with the company planning to submit a biologics license application in Q1 2027.
Eli Lilly's Zepbound (tirzepatide 10 mg and 15 mg) showed greater weight loss than Novo's Wegovy HD (semaglutide injection 7.2 mg) in an indirect treatment comparison, with Zepbound 15 mg users having over three times the odds of achieving at least 20% body-weight reduction.
Eli Lilly's Foundayo (orforglipron) showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison, potentially receiving modest upward valuation support.

Newcomers· Sep 29

Newcomers are excited about Eli Lilly's (LLY) growth, with one user mentioning a 51% increase in the company's stock price in a year.
Another user is focused on Eli Lilly's guidance implying a strong second half of the year, with revenue expected to be in the range of $21.1-22.1 billion per quarter.
Some newcomers are interested in the company's recent approvals and contracts, including the FDA approval for Onswik insulin and a $880,000 contract with $7.48 million revenue, which they see as a validation of the company's efforts.

Generated by AI

News

Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study

2h agoReuters

Opinion: Eli Lilly Stock Is a No-Brainer Pick to Buy on the Dip

This stock is worth loading up on whenever it's on the cheap side.

10h agoYahoo Finance

Eli Lilly Might Be the Next Stock I Buy | The Motley Fool

The company has a history of developing treatments that have achieved widespread adoption.

10h agoThe Motley Fool

Lilly's experimental drug cuts weight by 21% in diabetes trial

13h agoReuters

People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug

Participants who took the experimental drug retatrutide experienced the largest weight loss ever seen in a drug trial for diabetes.

14h agoNBC News

Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results

Two new studies on the experimental drug retatrutide show it helps overweight people lose weight, whether or not they have diabetes.

14h agotime.com

Also Discussed

Investors talking about LLY also mention

#	Name	Attention
1	Novo Nordisk A/S Sponsored ADRNVO	0.14%-0.04
2	Viking Therapeutics, Inc.VKTX	0.18%0
3	MTSR - Metsera, Inc.	——
4	Amgen Inc.AMGN	0.01%+0
5	Merck & Co., Inc.MRK	0.01%-0.06
6	Novartis AG Sponsored ADRNVS	0%-0.01
7	UnitedHealth Group IncorporatedUNH	0%-0.02
8	Pfizer Inc.PFE	0.04%-0.01
9	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
10	Hims & Hers Health, Inc.HIMS	0.17%+0.1

Eli Lilly and Company

Healthcare
Drug Manufacturers - General

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines for human health. The company focuses on major therapeutic areas including cardiometabolic health, oncology, immunology, neuroscience, and rare diseases, with a portfolio that spans treatments for diabetes, obesity, cancer, autoimmune conditions, and neurological disorders. Eli Lilly and Company also operates in animal health-related products in some markets, supporting a broader healthcare presence. Its business is centered on prescription medicines and biologic therapies, combining research, clinical development, and large-scale manufacturing to serve patients, healthcare providers, and health systems worldwide. Headquartered in Indianapolis, Indiana, Eli Lilly and Company is widely recognized for its role in advancing innovative treatments and maintaining a strong position in the global pharmaceutical market.

Website

Location

Lilly Corporate Center

Indianapolis, IN, 46285

United States

Social

What share of all stock conversation is about LLY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.16% +0.07	0.31% +0.23	0.1% -0.01	0.21% +0.08

Sep 29

Eli Lilly's once-weekly basal insulin, Onswik, has won US FDA approval, and Olumiant's label has been expanded to include adolescents with severe alopecia.
The company's incretin trends are strong, with a 48% increase in revenue and 60% increase in volume in Q2, and guidance implies H2 revenue of $21.1-22.1B a quarter.
Lilly's CEO has reported that a third of new GLP-1 pill patients are on Wegovy, and 700k seniors have started treatment after Medicare coverage, contributing to the stock's 51% increase in a year.

Generated by AI

Sentiment

Of the messages about LLY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	80% -18.56	96.91% +8.38	95.27% +7.94	90.14% +17.81
Bearish	20% +18.56	3.09% -8.38	4.73% -7.94	9.86% -17.81

Bullish· Sep 22

$LLY has a strong position in the oral GLP-1 market, with the company capturing 70% of new senior patients and its oral GLP-1 pill winning one-third of new GLP-1 pill starts.
$LLY is expected to see significant growth in the oral obesity opportunity, with the company's CEO stating that one-third of new GLP-1 pill patients are now choosing Foundayo.
$LLY's manufacturing capacity is being ramped up, with a new $6.5B Houston manufacturing facility being built to produce Foundayo's active ingredient, supporting the company's long-term supply plans.

Bearish· Aug 5

$LLY's EPS forecasts have been revised lower in recent weeks, creating space for a potential beat, but 80% of the Yes on the $6.79 bar looks high on this setup.
$LLY's performance is underperforming Novo Nordisk, with its stock price still in the 2021 range and down 12% over the last 5 years.
$LLY's GD1 program has been dropped, removing a potential player from the Gaucher disease race, and pipeline execution remains a concern for investors.

Generated by AI

Topics

Of the messages about LLY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Macro	0%	46.7%	39.87%	55.65%
Technical Analysis	0%	0.22%	0.92%	4.96%
Announcements	98.37%	3.33%	11.68%	8.89%
Controversies	0.81%	3.02%	5.01%	1.41%
Analysts	0%	46.73%	41.16%	23.45%
Earnings	0.81%	0.01%	1.36%	5.64%

Earnings· Aug 5

$LLY's Q2 earnings beat expectations, with revenue of $22.97B vs. $20.7B estimated, and adjusted EPS of $8.38 vs. $6.01 estimated.
The company raised its FY26 revenue guidance to $85B-$87B from $82B-$85B, driven by strong demand for its obesity drugs Mounjaro and Zepbound.
Mounjaro revenue was $9.9B, up 91% YoY, and Zepbound revenue was $4.9B, beating estimates of $4.6B.

Analysts· May 27

BofA Securities reiterates a Buy rating on LLY with a price target of $1251, citing the company's dominant market position in the GLP-1 category and underappreciated growth outlook.
The analyst believes LLY's growth prospects are being underappreciated by the market, with a promising obesity pipeline that could drive future growth.
The company's short-term price action after earnings can be brutal, but it doesn't always change the longer-term trend, according to the analyst.

Announcements· Sep 22

Eli Lilly broke ground on a $6.5B Houston facility to produce active ingredients for Foundayo and other medicines, with operations expected by 2030, creating 600+ permanent jobs and 4,000 temporary ones.
The company's fortunes have reversed since the 2021 arrival of Wegovy propelled its valuation above $600 billion, with shares tumbling more than 70% from their record highs due to stiff competition from US rival Eli Lilly.
Eli Lilly received full FDA approval for Inluriyo in ESR1-Mutated Breast Cancer, with a price target of $1,250 set by TD Cowen.

Controversies· Aug 12

Eli Lilly has filed six lawsuits against U.S. entities accused of selling retatrutide products, including compounding pharmacies and medical spas, and has referred over 200 individuals and entities to regulators.
The lawsuits signal Lilly's aggressive move to protect its pipeline ahead of potential approval, and could impact the grey market for retatrutide.
The company is pushing card processors to cut off the black-market sellers, and has urged platforms to block them, as it continues to crack down on the illegal sale of its experimental obesity drug.

Macro· May 12

Eli Lilly's partnership with Takeda has potential milestones of up to $2.1 billion and tiered double-digit royalties.
Eli Lilly's partnership with the company has potential milestones of up to $1.7 billion and tiered double-digit royalties.
Analysts have set an average price target for Eli Lilly of $9.

Technical Analysis· Aug 20

The stock broke through historical highs and demonstrated significant buying interest, with a 50% increase in volume compared to the average.
A potential head and shoulders pattern is forming, which could indicate a strong upward momentum and a possible target price of $1350.
The stock has a strong bullish momentum, with a confirmed breakout and a potential target of $1506.7 or higher, while dips proposed ended in the #bluebox area.

Generated by AI

Community

Of the messages about LLY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	8.98%	85.92%	69.57%	33.32%
Newcomers	91.02%	14.08%	30.43%	66.68%

Regulars· Sep 29

Eli Lilly's Retatrutide showed a 20.8% average weight loss over 80 weeks in phase 3 trials, with the company planning to submit a biologics license application in Q1 2027.
Eli Lilly's Zepbound (tirzepatide 10 mg and 15 mg) showed greater weight loss than Novo's Wegovy HD (semaglutide injection 7.2 mg) in an indirect treatment comparison, with Zepbound 15 mg users having over three times the odds of achieving at least 20% body-weight reduction.
Eli Lilly's Foundayo (orforglipron) showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison, potentially receiving modest upward valuation support.

Newcomers· Sep 29

Newcomers are excited about Eli Lilly's (LLY) growth, with one user mentioning a 51% increase in the company's stock price in a year.
Another user is focused on Eli Lilly's guidance implying a strong second half of the year, with revenue expected to be in the range of $21.1-22.1 billion per quarter.
Some newcomers are interested in the company's recent approvals and contracts, including the FDA approval for Onswik insulin and a $880,000 contract with $7.48 million revenue, which they see as a validation of the company's efforts.

Generated by AI

Eli Lilly

Social

Sep 29

Bullish· Sep 22

Bearish· Aug 5

Earnings· Aug 5

Analysts· May 27

Announcements· Sep 22

Controversies· Aug 12

Macro· May 12

Technical Analysis· Aug 20

Regulars· Sep 29

Newcomers· Sep 29

Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study

Opinion: Eli Lilly Stock Is a No-Brainer Pick to Buy on the Dip

Eli Lilly Might Be the Next Stock I Buy | The Motley Fool

Lilly's experimental drug cuts weight by 21% in diabetes trial

People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug

Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results

Also Discussed

Eli Lilly and Company

Company Information

Location

Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study

Opinion: Eli Lilly Stock Is a No-Brainer Pick to Buy on the Dip

Eli Lilly Might Be the Next Stock I Buy | The Motley Fool

Lilly's experimental drug cuts weight by 21% in diabetes trial

People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug

Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results

Also Discussed

Social

Sep 29

Bullish· Sep 22

Bearish· Aug 5

Earnings· Aug 5

Analysts· May 27

Announcements· Sep 22

Controversies· Aug 12

Macro· May 12

Technical Analysis· Aug 20

Regulars· Sep 29

Newcomers· Sep 29